Peer-influenced content. Sources you trust. No registration required. This is HCN.

ReachMDIntegrating Immune Checkpoint Therapy Into the Management of Resectable Melanoma

Lack of Concordance Between Radiologic and Pathologic Responses in Neoadjuvant ICI Treatment of Melanoma: How Do I Assess Radiologic Progression?

After taking part in this CME activity, medical oncologists, surgeons, dermatologists, oncology nurses, oncology pharmacists, and other members of the interprofessional team who manage patients with melanoma should be better able to:

  • Find melanoma patients who may benefit from neoadjuvant and adjuvant immune checkpoint inhibitor (ICI) treatment.
  • Explain the biomarkers utilized in research and practice to predict response to ICIs in perioperative neoadjuvant and adjuvant settings, as well as the surrogate endpoints used in clinical trials to evaluate ICI efficacy.
  • Use information from ICI neoadjuvant and adjuvant clinical trials to guide treatment plans for patients with resectable melanoma.
  • Determine how to manage toxicities’ risks and potential side effects, such as pseudoprogression and hyperprogression, in certain situations.
  • Identify the unresolved problems with the ideal dose, time, and schedule
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form